OTC Medicines

CHPA opposes mandatory manufacturer-funded drug take-back programs as they threaten the affordability of OTC medications that consumers rely on as the first line of defense against common ailments.

FDA Announcement of a proposed safety-based Administrative Order that proposes to add a skin allergy warning to labeling requirements for acetaminophen-containing drug products.

The bipartisan federal Combat Meth Epidemic Act strikes the proper policy balance between restricting pseudoephedrine access for illicit use without unduly burdening consumers seeking safe, effective cold relief. Therefore, state legislators should refrain from overriding federal guidelines requiring prescriptions for these legitimate over-the-counter medications.

This proposed safety administrative order addresses the GRASE status of OTC oral health care drug products containing benzocaine alone or with phenol preparations labeled for anesthetic/analgesic indications (21 CFR 356).

Lawmakers should refrain from imposing unnecessary restrictions limiting consumer purchase quantities or behind-the-counter placement for loperamide, as leading manufacturers have already implemented package adjustments to limit potential abuse of these medications by consumers.